New obesity drug candidate cagrilintide gets closer look in early trial
NCT ID NCT07605052
First seen May 24, 2026 · Last updated Jun 22, 2026 · Updated 4 times
Summary
This early-stage study will compare two different versions of the drug cagrilintide in 50 adults with overweight or obesity. Participants will receive injections of either version for several weeks, and researchers will measure how the drug builds up in the body. The goal is to see which version works better for future weight-loss treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Celerion, Phoenix
Tempe, Arizona, 85283, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cagrilintide
What this could lead to
If successful, this study could help select the best version of cagrilintide for future weight-loss treatments.
What could go wrong
This is an early Phase 1 trial with only 50 participants, focused on drug levels in the body, not weight loss. It is too early to know if it will lead to an effective treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.